Literatur
-
1 National Institute
of Infectious Diseases .The Jordan report: accelerated
development of vaccines. www.niaid.nih.gov/publications/jordan/
-
2
Mc Gregor R.
Herpes
zoster, chickenpox and cancer in general practice.
Br
Med J.
1957;
1
84
-
3
Takashi M. et al .
Live vaccine used to prevent the spread
of varicella in children in hospital.
Lancet.
1974;
2
228-234
-
4
Lawrence R. et al .
Risk of Zoster after vaccination of children
with leucemia.
New Engl J Med.
1988;
318
543-548
-
5
Berger R. et
al .
Enhancement of varicella-zoster-specific immune
response in the elderly by boosting with varicella vaccine.
J Infect
Dis.
1984;
149
647
-
6
Berger R. et
al .
A dose response study of live attenuated varicella-zoster
virus (OKA strain) vaccine administered to adults 55 years of age
and older.
J Infect Dis.
1998;
178
(Suppl 1)
99-103
-
7
Hayward A R. et al .
Immune response to secondary immunization
with live or inactivated VZV vaccine in elderly adults.
Viral mmunol.
1994;
7
31-36
-
8
Levin M J. et al .
Use of live attenuated varicella vaccine
to boost varicella-specific immune responses in seropositive people
55 years of age or older. Duration of booster effect.
J
Infect Dis.
1998;
178
(Suppl
1)
109-112
Autor
Priv.-Doz. Dr. med. J. Niebel
Fachbereich Infektiologie, Stiftung Deutsche Klinik
für Diagnostik
Aukammallee 33
65191
Wiesbaden
